Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,922.00    -6.00 (-0.20%)
Bid:
2,902.00
Ask:
2,906.00
Spread: 4.00 (0.138%)
Market Cap: £1.61b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

16 Apr 2025 07:00

RNS Number : 1833F
Oxford Instruments PLC
16 April 2025
 

 

 

Oxford Instruments plc

Full-year trading update - 16 April 2025

 

Strong H2 delivered - full-year trading in line with expectations

Good progress on execution of the strategy

 

 

Oxford Instruments plc, a leading provider of scientific technology and expertise to academic and commercial partners, is today issuing a trading update for the year ended 31 March 2025.

 

We have delivered a strong full-year performance, in line with expectations. This has been underpinned by continued momentum in order intake and good progress on the execution of our strategy. We are seeing the benefits of the actions we have taken to drive operational excellence, improve commercial execution, and bring a greater focus on our costs.

 

Revenue growth in the second half has been strong, as anticipated, resulting in full-year revenue growth expected to be around +9% at constant currency1 (+6% at actual rates) versus the prior year. Demand has remained healthy, with 3% year-on-year order growth at constant currency.

 

Full-year adjusted operating profit2 is expected to be up around 13% on a constant currency basis (3% at actual rates), in line with market expectations. Group constant currency adjusted operating margin is expected to be around 17.8% (16.5% at actual rates), up 70 bps year on year with margin progress in both divisions.

 

Our Imaging & Analysis division, which represents two-thirds of Group revenue and around 90% of its operating profit, has performed well, growing both orders and revenue whilst maintaining its excellent operating margin above 24% at constant currency. Semiconductor revenues have grown strongly and, along with materials analysis, have offset continuing softness in the healthcare and life science end market.

 

Our Advanced Technologies division has delivered strong double digit constant currency revenue growth. As anticipated, we delivered a number of large customer orders in our quantum business which, together with operational improvements, resulted in a return to profitability. We have also continued to grow our compound semiconductor business in its new facility and increase our Tier 1 customer base, achieving both double-digit revenue growth and a margin improvement.

Richard Tyson, CEO, commented:

 "I am very pleased with how the team have embraced the strategy, delivering strong results despite the macro volatility seen in H2 and the execution of our pivot away from certain market segments in China."

"We continue to closely monitor and adapt to the potential impacts of macro events. Oxford Instruments' growth and resilience is underpinned by our diversified portfolio of market-leading technologies, deployed in multiple structurally growing sectors across all the major geographies. In addition, there are significant opportunities within our own control, as we accelerate our operational transformation programme, work to simplify and standardise our business, and drive a continued critical focus on product profitability."

Oxford Instruments management will present its full-year results to analysts and investors at Deutsche Numis, 45 Gresham Street, London EC2V 7BF, on 10 June 2025.

 

Notes:

1. Constant currency numbers are prepared on a month-by-month basis using the translational and transactional exchange rates which prevailed in the previous year rather than the actual exchange rates which prevailed in the year. Transactional exchange rates include the effect of our hedging programme.

2. Adjusted items exclude the amortisation and impairment of acquired intangible assets, acquisition items, business reorganisation costs, other significant non‑recurring items, and the mark-to-market movement of financial derivatives.

 

The financial information in this trading update is unaudited.

LEI: 213800J364EZD6UCE231

 

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Head of Investor Relations Stephen.lamacraft@oxinst.com 

 

MHP Group

Katie Hunt/Tim Rowntree/ 07710 117517

Veronica Farah oxfordinstruments@mhpgroup.com

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide with market-leading scientific technology and expertise across its key market segments: materials analysis, semiconductors, and healthcare & life science. Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to accelerate the breakthroughs that create a brighter future for our world. The vigorous search for new ways to make our world greener, healthier and more productive is driving unprecedented levels of R&D investment in new materials and techniques to support productivity and decarbonisation worldwide, creating a significant opportunity for Oxford Instruments to grow. Oxford Instruments holds a unique position to anticipate global drivers and connect academic researchers with commercial applications engineers, acting as a catalyst that powers real world progress. Founded in 1959 as the first technology business to be spun out from Oxford University, Oxford Instruments is now a global, FTSE250 company listed on the London Stock Exchange (OXIG). For more information, visit www.oxinst.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKPBDFBKDPQD
Date   Source Headline
6th Jun 20172:14 pmPRNTotal Voting Rights
4th May 20171:56 pmPRNTotal Voting Rights
26th Apr 20177:30 amRNSSale of Industrial Analysis business to HHT
13th Apr 20177:00 amRNSTrading Statement
3rd Apr 20173:25 pmPRNTotal Voting Rights
27th Feb 20179:34 amPRNHolding(s) in Company
2nd Feb 20171:25 pmPRNTotal Voting Rights
31st Jan 20174:31 pmPRNHolding(s) in Company
30th Jan 20174:43 pmPRNHolding(s) in Company
3rd Jan 201711:30 amPRNBlocklisting - Interim Review
18th Nov 20167:00 amRNSDisposal
15th Nov 20167:00 amRNSHalf-year Report
14th Nov 201612:52 pmPRNDirector Declaration
1st Nov 201611:07 amPRNTotal Voting Rights
26th Oct 20167:00 amPRNHolding(s) in Company
14th Sep 201610:17 amPRNResult of AGM
13th Sep 20167:00 amRNSAGM Statement
1st Aug 20164:14 pmPRNTotal Voting Rights
5th Jul 20161:26 pmPRNTotal Voting Rights
5th Jul 20161:19 pmPRNBlocklisting - Interim Review
21st Jun 20162:51 pmPRNDirector/PDMR Shareholding
15th Jun 20167:00 amRNSFinal Results
13th Jun 20161:44 pmPRNDirector/PDMR Shareholding
7th Jun 20163:31 pmRNSDirectorate Change
12th May 20164:26 pmPRNDirector/PDMR Shareholding
9th May 20167:00 amRNSDirectorate Change
18th Apr 20167:00 amPRNDirector/PDMR Shareholding
11th Apr 201610:49 amPRNDirectorate Change
14th Mar 20163:54 pmPRNDirector/PDMR Shareholding
3rd Mar 201611:03 amPRNHolding(s) in Company
24th Feb 20163:47 pmPRNHolding(s) in Company
24th Feb 20167:00 amRNSDirector Declaration & Directorate Change
23rd Feb 201611:52 amPRNNotification of Home State
16th Feb 201611:07 amPRNDirector/PDMR Shareholding
12th Feb 20167:00 amRNSAppointment of Group Finance Director
2nd Feb 20167:00 amRNSAppointment of Non-Executive Director
22nd Jan 20167:00 amRNSTrading Statement
15th Jan 20167:00 amRNSNotice of Trading Update
14th Jan 20161:51 pmPRNDirector/PDMR Shareholding
4th Jan 201612:07 pmPRNBlocklisting - Interim Review
1st Dec 201510:37 amPRNHolding(s) in Company
26th Nov 20153:41 pmPRNHolding(s) in Company
24th Nov 20157:00 amRNSDisposal
12th Nov 20152:23 pmPRNDirector/PDMR Shareholding
10th Nov 20153:23 pmPRNHolding(s) in Company
10th Nov 20157:01 amRNSDirectorate Changes
10th Nov 20157:00 amRNSHalf Yearly Report
27th Oct 201510:06 amRNSReplacement re: Directorate Change
27th Oct 20157:00 amRNSDirectorate Change
14th Oct 201511:09 amPRNDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.